JP-MPSC@EC2611A

MICROPORT released FY2025 Q3 earnings on March 31, 2026 (BJT) with actual revenue of HKD 0 and EPS of HKD 0

MICROPORT released FY2025 9 Months earnings on March 31, 2026 (BJT) with actual revenue of HKD 4.279 B and EPS of HKD -0.2206

MICROPORT released FY2025 earnings on March 31 After-Market (BJT), actual revenue HKD 7.758 B (forecast HKD 8.759 B), actual EPS HKD 0.2019 (forecast HKD -0.219)

MICROPORT released FY2025 Q4 earnings on March 31 After-Market (BJT) with actual revenue HKD 0 and EPS HKD 0

MICROPORT to Release FY2025 Earnings on March 31 After-Market (BJT), Forecast Revenue HKD 8.806 B, EPS HKD -0.2195

MicroPort Expected to Turn Profitable in 2025

MicroPort Expands in Cardiovascular Interventions and Other Business Sectors

MicroPort Sees 119% Return in Past Year but Reports 0.7% Revenue Decline

Citi Reiterates Buy Rating on MicroPort

China Everbright 上调 MicroPort 的净利润预期并维持买入评级

MicroPort Cardiovascular Announces 350% TAVI Procedure Growth and Plans Acquisition

Microport Cardiovascular Announces One-Year Follow-Up Results of AltaValveTM and Completes Financing

MicroPort Medical Technology Deconsolidates Subsidiary

MicroPort Surgical Robot Toumai Secures Over 230 Global Orders

MicroPort Cardiovascular Completes Merger with MicroPort CRM

MicroPort Cardiovascular Flow Tech Acquires MicroPort Cardiac Rhythm Management

MicroPort Cardiovascular Reorganizes Board to Enter Heart Failure Treatment Market

MicroPort Medical Cardiovascular Shareholders Approve Merger with CRM and Heart Rhythm Management

MicroPort Obtained CE Mark Approval for SmartView Connect™

JPMorgan Raises Stake in MicroPort Medical

FINELAND LIVING

GPIXEL

WK GROUP

MAX SIGHT GROUP

I.CENTURY HLDG

HAO BAI INTL

TEAMWAY INTL GP

GEMILANG INTL

DAISHOMICROLINE

00853

MicroPort Scientific (SEHK:853) has entered into two international distribution agreements, potentially increasing its annual transaction caps for cardiovascular products. Currently trading at HK$9.44, the company has experienced a 2.16% one-day return but a 24.05% decline over 90 days. With a revenue of US$994.9 million and a loss of US$233.8 million, it trades at a price-to-sales ratio of 2.3x, significantly lower than industry peers. Analysts suggest it is undervalued, with a fair value estimate of HK$18.13 per share, indicating a 48% discount. However, risks remain due to reliance on specific markets and ongoing losses.

Simplywall

MICROPORT

A Look At MicroPort Scientific (SEHK:853) Valuation After New Global Distribution Agreements

562600

159883

159898

MicroPort Scientific Corporation (853.HK) technical chart shows a clear weak pattern. The daily MACD death cross indicates a slowdown in momentum, with the market approaching the bottom support level but not yet showing a rebound trend. The shrinking trading volume indicates a clear stance of capital waiting and observing. The pharmaceutical sector is under pressure from policy adjustments and a slowdown in overseas market demand, creating pressure on the company's profitability. Future market focus factors include the long-term growth prospects of the industry and changes in the policy environment

Technical Forecast

ChinaAMC CSI All Share Health Care Devices ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Morning Trend | MICROPORT's technical indicators weaken, and the risk of wave-type decline still exists

688016

MicroPort Scientific reported 2025 sales of US$994.91 million and net income of US$48.52 million. The company announced a leadership change, with Dr. Zhaohua Chang stepping down as CEO and Jonathan W. Chen taking over as rotating CEO. This leadership refresh aims to align operational decisions with global expansion goals. While the return to profitability is promising, the new structure introduces execution risks. Analysts suggest the stock may be trading above fair value, indicating potential downside despite a positive investment narrative.

Endovastec

What MicroPort Scientific (SEHK:853)'s Profit Return and Rotating CEO Overhaul Means For Shareholders

02160

688351

02172

02252

Bank of America Securities has lowered the target price for MICROPORT to 13.9 yuan, reiterating a "Buy" rating. It expects total revenue in 2025 to be USD 1.105 billion, with a year-on-year increase of 6% after excluding foreign exchange factors. Its "GloMatrix" platform has achieved breakeven, and revenue for the fiscal year 2025 is expected to grow by 78.8% to 163.9 million yuan. Due to the exclusion of MICROPORT NEURO from the consolidated financial statements, revenue forecasts for 2026 to 2028 have been reduced by 10.9% to 12.9%. At the same time, gross margin forecasts have been raised by 1.9 to 2.1 percentage points, and operating expense ratio forecasts have been raised by 11.5 to 12.6 percentage points

AASTOCKS

MP CARDIOFLOW-B

MICROPORT EP

MICROPORT NEURO

MircroPort Medbot-B

Bank of America Securities lowers the target price for MicroPort to 13.9 yuan, reiterating a "Buy" rating

40168

MicroPort Sets Up Global Executive Committee and Reshapes Top Management Roles

Tip Ranks

MICROPORT POF-D

First Trust NYSE Arca Biotech Index Fd

MICROPORT B2812

MicroPort Sets Up Global Executive Committee and Reshapes Top Management Roles

MicroPort announced its 2025 annual performance, with revenue of USD 1.105 billion, an increase of 7.2% year-on-year; gross profit of USD 635 million, an increase of 10.5%. It recorded a net profit of USD 48.52 million, compared to a loss of USD 214 million in the previous year, turning a loss into a profit; earnings per share of 2.59 cents. No final dividend will be distributed

"Performance" MICROPORT achieved a net profit of USD 48.52 million for the entire year, turning a loss into a profit

MicroPort CardioFlow Medtech Corp. has announced a change in its reporting currency from Renminbi to U.S. dollars to align with its globalization strategy and the contribution of its subsidiary, MicroPort Cardiac Rhythm Management Limited. This change aims to provide clearer financial performance insights for shareholders and investors, with prior-year figures restated in USD starting with the 2025 annual report. The current analyst rating for the stock (HK:2160) is a Hold, with a price target of HK$0.76.

MicroPort CardioFlow Switches Reporting Currency to U.S. Dollars

Shares of MicroPort Endovascular MedTech Group surged 10.2% to CNY111.80 after the US FDA granted Breakthrough Device Designation to its innovative stent graft system, expediting market approval. The Hector Multi-Branch Thoracic Aortic Stent Graft System aims for minimally invasive treatment of thoracic aortic lesions. MicroPort reported a 12% rise in net profit to CNY563 million last year, driven by innovative product launches and a 55% increase in overseas sales. The device has received EU certification and is in clinical trials in China, addressing high-risk aortic arch lesions with less invasive methods.

Yicai

China's MicroPort Soars After US Grants Its New Stent Breakthrough Device Status

MICROPORT announced that its 40.32% subsidiary Endovastec achieved revenue of RMB 1.351 billion for the fiscal year 2025, an increase of 12% year-on-year. The net profit attributable to shareholders was RMB 563 million, a growth of 12.2%

MicroPort earned 563 million RMB last year, an increase of 12.2%

MicroPort CardioFlow Medtech Corp. has received shareholder approval for a share consolidation, reducing issued shares from approximately 6.37 billion to about 1.27 billion. This consolidation will take effect on 24 February 2026, aiming to enhance trading efficiency and price perception. Existing blue share certificates will remain valid but not for trading after new light-gold certificates are issued. The company will also adjust share options accordingly. The latest analyst rating for the stock (HK:2160) is a Sell with a price target of HK$0.74.

MicroPort CardioFlow Wins Shareholder Approval for Share Consolidation Effective 24 February

Reuters

MicroPort CardioFlow Merges with MicroPort CRM

MICROPORT opened high today at 6.34%, reaching a maximum of 13.95 yuan. It is currently reported at 13.45 yuan, up 7.95%, with a trading volume of 15.7865 million shares, involving a capital of 213 million yuan. The company recently issued a profit warning, expecting to turn a profit in the fiscal year 2025, with a net profit of no less than 20 million USD, compared to a net loss of 268 million USD in the previous year

MicroPort rose nearly 8% after issuing a profit warning, expecting to turn a profit last year

JP-MPSC@EC2611A(28417.HK)

JP-MPSC@EC2611A Stock Performance Chart

A Look At MicroPort Scientific (SEHK:853) Valuation After New Global Distribution Agreements

Morning Trend | MICROPORT's technical indicators weaken, and the risk of wave-type decline still exists

What MicroPort Scientific (SEHK:853)'s Profit Return and Rotating CEO Overhaul Means For Shareholders

Bank of America Securities lowers the target price for MicroPort to 13.9 yuan, reiterating a "Buy" rating

MicroPort Sets Up Global Executive Committee and Reshapes Top Management Roles